Galapagos NV (GLPG) Analysts See $-0.70 EPS; Actuant (ATU) Shorts Increased By 2.48%

February 16, 2018 - By Nellie Frank

Analysts expect Galapagos NV (NASDAQ:GLPG) to report $-0.70 EPS on February, 23.They anticipate $1.75 EPS change or 166.67% from last quarter’s $1.05 EPS. After having $-0.85 EPS previously, Galapagos NV’s analysts see -17.65% EPS growth. The stock increased 1.31% or $1.51 during the last trading session, reaching $116.73. About 110,074 shares traded or 7.65% up from the average. Galapagos NV (NASDAQ:GLPG) has risen 65.27% since February 16, 2017 and is uptrending. It has outperformed by 48.57% the S&P500.

Actuant Corporation (NYSE:ATU) had an increase of 2.48% in short interest. ATU’s SI was 6.24M shares in February as released by FINRA. Its up 2.48% from 6.08 million shares previously. With 269,500 avg volume, 23 days are for Actuant Corporation (NYSE:ATU)’s short sellers to cover ATU’s short positions. The SI to Actuant Corporation’s float is 10.71%. The stock increased 1.05% or $0.25 during the last trading session, reaching $24. About 481,375 shares traded. Actuant Corporation (NYSE:ATU) has risen 0.16% since February 16, 2017 and is uptrending. It has underperformed by 16.54% the S&P500.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company has market cap of $5.61 billion. The Company’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis patients in Phase Ib trial. It currently has negative earnings. The firm has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106.

Among 9 analysts covering Galapagos NV (NASDAQ:GLPG), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Galapagos NV had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by BTIG Research on Wednesday, February 7 with “Buy”. Zacks upgraded it to “Hold” rating and $67 target in Tuesday, August 11 report. On Wednesday, June 21 the stock rating was maintained by Stifel Nicolaus with “Hold”. The stock of Galapagos NV (NASDAQ:GLPG) has “Buy” rating given on Friday, October 27 by Stifel Nicolaus. The firm earned “Hold” rating on Thursday, September 14 by RBC Capital Markets. The firm has “Hold” rating given on Thursday, January 5 by Stifel Nicolaus. The stock of Galapagos NV (NASDAQ:GLPG) has “Buy” rating given on Friday, August 11 by Stifel Nicolaus. The stock of Galapagos NV (NASDAQ:GLPG) has “Buy” rating given on Tuesday, August 30 by Janney Capital. Stifel Nicolaus maintained Galapagos NV (NASDAQ:GLPG) rating on Thursday, September 14. Stifel Nicolaus has “Buy” rating and $120.0 target. Nomura maintained the shares of GLPG in report on Friday, August 11 with “Buy” rating.

Investors sentiment decreased to 1.37 in Q3 2017. Its down 0.35, from 1.72 in 2017Q2. It is negative, as 13 investors sold Actuant Corporation shares while 47 reduced holdings. 22 funds opened positions while 60 raised stakes. 62.75 million shares or 3.05% less from 64.72 million shares in 2017Q2 were reported. Nationwide Fund Advsr holds 0% or 42,084 shares in its portfolio. Moreover, Geode Mgmt Limited Liability Co has 0% invested in Actuant Corporation (NYSE:ATU) for 497,921 shares. Fuller & Thaler Asset Management Inc holds 3.15M shares. Panagora Asset Mngmt invested in 58,042 shares or 0.01% of the stock. Mairs & Pwr invested in 450,145 shares or 0.14% of the stock. Cove Street Cap Limited Com holds 560,001 shares or 1.6% of its portfolio. Oppenheimer And accumulated 0.04% or 58,357 shares. Parkside Fin Bank And has invested 0% in Actuant Corporation (NYSE:ATU). Invesco Ltd invested in 0% or 112,546 shares. Kennedy Capital Mgmt stated it has 0.02% of its portfolio in Actuant Corporation (NYSE:ATU). Brown Brothers Harriman, New York-based fund reported 8,685 shares. Natixis holds 0% of its portfolio in Actuant Corporation (NYSE:ATU) for 8,905 shares. Clarkston Prns Ltd Liability invested in 2.54M shares. Victory Cap Mngmt Inc invested in 424,695 shares or 0.02% of the stock. Tiaa Cref Invest Mgmt Lc holds 157,351 shares.

Actuant Corporation designs, manufactures, and distributes a range of industrial products and systems worldwide. The company has market cap of $1.44 billion. It operates through three divisions: Industrial, Energy, and Engineered Solutions. It currently has negative earnings. The Industrial segment is primarily involved in the design, manufacture, and distribution of branded hydraulic and mechanical tools to the maintenance, industrial, infrastructure, and production automation markets under the Enerpac, Simplex, Precision-Hayes, Milwaukee Cylinder, and Larzep brand names.

Among 18 analysts covering Actuant (NYSE:ATU), 6 have Buy rating, 0 Sell and 12 Hold. Therefore 33% are positive. Actuant had 45 analyst reports since August 26, 2015 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, June 22. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, November 14. The stock of Actuant Corporation (NYSE:ATU) earned “Hold” rating by RBC Capital Markets on Monday, June 5. The stock has “Hold” rating by RBC Capital Markets on Tuesday, July 25. BMO Capital Markets maintained Actuant Corporation (NYSE:ATU) on Friday, June 9 with “Hold” rating. On Tuesday, April 5 the stock rating was initiated by BMO Capital Markets with “Market Perform”. Robert W. Baird maintained Actuant Corporation (NYSE:ATU) on Tuesday, October 31 with “Buy” rating. SunTrust downgraded Actuant Corporation (NYSE:ATU) on Tuesday, March 8 to “Neutral” rating. As per Wednesday, June 21, the company rating was upgraded by J.P. Morgan. Barclays Capital initiated Actuant Corporation (NYSE:ATU) on Friday, September 25 with “Equal-Weight” rating.

Since September 28, 2017, it had 0 buys, and 2 sales for $153,218 activity. 876 shares were sold by Rennie Stephen, worth $22,268. Wozniak Ted also sold $130,950 worth of Actuant Corporation (NYSE:ATU) on Tuesday, October 10.